sponsored byAAAS Golden Fund

EurekAlert!, a service of AAAS
Home About us
Advanced Search
1-May-2016 04:10
US Eastern Time

Username:

Password:

Register

Forgot Password?

Press Releases

Breaking News

Science Business

Grants, Awards, Books

Meetings

Multimedia

Science Agencies
on EurekAlert!

US Department of Energy

US National Institutes of Health

US National Science Foundation

Calendar

Submit a Calendar Item

Subscribe/Sponsor

Links & Resources

Portals

RSS Feeds

Accessibility Option On

Options

Portal Home

Glossary

Background Articles

Research Papers

Meetings

Links & Resources

Disease in the Developing World

News Releases

Key: Meeting M      Journal J      Funder F

Showing releases 126-150 out of 1221.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

Public Release: 24-Feb-2016
2016 68th AAN Annual Meeting
Most Ebola survivors in study experienced brain symptoms 6 months after infection
Most of the 82 Ebola survivors in a new study from the world's largest Ebola outbreak had brain symptoms more than six months after the initial infection. The preliminary results will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. The study is part of the larger Prevail III study, which follows patients with prior Ebola virus disease and their close contacts who serve as study controls.

Contact: Rachel Seroka
rseroka@aan.com
612-928-6129
American Academy of Neurology

Public Release: 23-Feb-2016
2016 Conference on Retroviruses and Opportunistic Infections
Study: Experimental Ebola drug ZMapp may benefit patients, but insufficient data
According to initial results from a randomized, controlled trial of the experimental Ebola treatment ZMapp, the monoclonal antibody cocktail was well-tolerated and showed promise. Due to decreasing incidence in Ebola, the study could not enroll enough volunteers to determine definitively whether it is a better treatment for Ebola virus disease than supportive care only. Initial findings from the clinical trial known as PREVAIL II were presented today at the Conference on Retroviruses and Opportunistic Infections in Boston.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 23-Feb-2016
2016 Conference on Retroviruses and Opportunistic Infections
Ebola survivor study yields insights on complications of disease
Preliminary findings from PREVAIL III, a study of Ebola virus disease (EVD) survivors being conducted in Liberia, indicate that both Ebola survivors and their close contacts have a high burden of illness. However, the prevalence of eye, musculoskeletal, and neurological complications was greater among the individuals who survived EVD.
NIH/National Institute of Allergy and Infectious Diseases

Contact: NIAID News Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 23-Feb-2016
2016 Conference on Retroviruses and Opportunistic Infections
Experimental Ebola vaccines well tolerated, immunogenic in phase 2 study
Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial called PREVAIL I. These findings were presented by one of the co-principal investigators, Fatorma Bolay, Ph.D., director of the Liberian Institute for Biomedical Research, this evening at the Conference on Retroviruses and Opportunistic Infections in Boston.
NIH/National Institute of Allergy and Infectious Diseases

Contact: NIAID News Office
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 23-Feb-2016
23rd Conference on Retroviruses and Opportunistic Infections
NIH-funded study finds effect of PrEP on bone density is reversible
The slight loss in bone mineral density associated with HIV pre-exposure prophylaxis (PrEP) antiretroviral use is reversible in young adult patients who stop taking the drugs, according to findings presented by researchers today at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. PrEP is an HIV prevention strategy in which at-risk HIV-negative people take a daily pill of Truvada, which contains the antiretroviral drugs tenofovir and emtricitabine, to prevent them from becoming infected.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Judith Lavelle
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 23-Feb-2016
ACS Nano
Counting molecules with an ordinary cell phone
The new visual readout method to count individual nucleic acid molecules within a sample can be performed by any cell-phone camera.
Defense Advanced Research Projects Agency, National Institutes of Health, NIH/National Institute of Biomedical Imaging and Bioengineering, Burroughs Wellcome Fund, National Science Foundation

Contact: Deborah Williams-Hedges
debwms@caltech.edu
626-395-3227
California Institute of Technology

Public Release: 23-Feb-2016
mBio
Bacteria overgrowth could be major cause of stunting in children
Excessive growth of bacteria in the small intestine could be damaging the gut of young children, leading to stunting, scientists from the US and Bangladesh have discovered.

Contact: Josh Barney
jdb9a@virginia.edu
434-906-8864
University of Virginia Health System

Public Release: 23-Feb-2016
EBioMedicine
Dietary link to stunted growth identified
A team of researchers has found that inadequate dietary intake of essential amino acids and the nutrient choline is linked to stunting, a debilitating condition that affects millions of children worldwide.
National Institutes of Health, Intramural Research Program of the National Institute on Aging, Children's Discovery Institute of Washington University and St. Louis Children's Hospital, Hickey Family Foundation

Contact: Judy Martin Finch
martinju@wustl.edu
314-286-0105
Washington University School of Medicine

Public Release: 23-Feb-2016
Society of Critical Care Medicine's 45th Critical Care Congress
JAMA
Feinstein Institute researcher presents new definitions for sepsis and septic shock
Clifford S. Deutschman, MS, MD, vice chair of research in the Department of Pediatrics at Cohen Children's Medical Center and an investigator at The Feinstein Institute for Medical Research, presented new definitions and clinical criteria for sepsis and septic shock at the Society of Critical Care Medicine's (SCCM) 45th Critical Care Congress in Orlando, FL. He was also corresponding author for an article outlining the findings that was published February 23 in The Journal of the American Medical Association.

Contact: Emily Ng
eng3@nshs.edu
516-562-2670
Northwell Health

Public Release: 23-Feb-2016
2016 Conference on Retroviruses and Opportunistic Infections
Option B+ to prevent maternal transmission of HIV shows rise in women initiating therapy
The first findings from a study in the Kingdom of Swaziland on a new approach to reduce mother to child transmission of HIV were presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston. show that implementation of Option B+ greatly increased the number of women initiating ART and dramatically improved ART coverage among pregnant women.
USAID, PEPFAR

Contact: Stephanie Berger
sb2247@columbia.edu
212-305-4372
Columbia University's Mailman School of Public Health

Public Release: 23-Feb-2016
EBioMedicine
Food-based proteins discovered as key to child malnutrition in developing countries
Contrary to popular belief among world relief workers, children in developing countries may not be eating enough protein, which could contribute to stunted growth, a Johns Hopkins-directed study suggests.

Contact: Marin Hedin
mhedin2@jhmi.edu
410-502-9429
Johns Hopkins Medicine

Public Release: 23-Feb-2016
Proceedings of the Royal Society B
Tackling Zika -- using bacteria as a Trojan horse
Bacteria in the gut of disease-bearing insects -- including the mosquito which carries the Zika virus -- can be used as a Trojan horse to help control the insects' population, new research at Swansea University has shown. The results showed declines in fertility of up to 100 percent and an increase of 60 percent in the mortality rate of larvae, among the insects studied. The findings offer the prospect of a much more targeted approach to insect control.

Contact: Kevin Sullivan
k.g.sullivan@swansea.ac.uk
Swansea University

Public Release: 23-Feb-2016
PLOS Medicine
Health and development in infants after mefloquine antimalarial treatment during pregnancy
Early development does not appear to be affected in children born to mothers who were treated with the antimalarial mefloquine during pregnancy compared to children of mothers treated with sulfadoxine-pyrimethamine, according to research appearing this week in PLOS Medicine.

Contact: PLOS Medicine
medicinepress@plos.org
PLOS

Public Release: 22-Feb-2016
2016 Conference on Retroviruses and Opportunistic Infections
New England Journal of Medicine
Vaginal ring provides partial protection from HIV in large multinational trial
A ring that continuously releases an experimental antiretroviral drug in the vagina safely provided a modest level of protection against HIV infection in women, a large clinical trial in four sub-Saharan African countries has found. The ring reduced the risk of HIV infection by 27 percent in the study population overall and by 61 percent among women ages 25 years and older, who used the ring most consistently.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Laura S. Leifman
laura.sivitz@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Public Release: 22-Feb-2016
2016 Conference on Retroviruses and Opportunistic Infections
Two large studies show IPM's monthly vaginal ring helps protect women against HIV
Two large Phase III clinical trials -- The Ring Study and ASPIRE -- have shown that a monthly vaginal ring containing the antiretroviral drug dapivirine can safely help prevent HIV-1 infection in women. Developed by the nonprofit International Partnership for Microbicides (IPM), the monthly ring is the first long-acting HIV prevention method designed for women, who bear the greatest burden of the global HIV/AIDS epidemic. IPM plans to apply for regulatory approval to license the product.
Ministry of Foreign Affairs of Denmark, Flanders Department of Foreign Affairs, Irish Aid, Ministry of Foreign Affairs of the Netherlands, Norwegian Agency for Development Cooperation, United Kingdom Department for International Development

Contact: Holly Seltzer
hseltzer@ipmglobal.org
301-608-4277
International Partnership for Microbicides (IPM)

Public Release: 22-Feb-2016
AIDS
One drug used to prevent HIV transmission during pregnancy shows evidence of developmental effects
The antiretroviral drug atazanavir -- sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy -- may have small but significant effects on infant development, reports a study in the journal AIDS, official journal of the International AIDS Society. AIDS is published by Wolters Kluwer.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 22-Feb-2016
ACS Nano
A portable device for rapid and highly sensitive diagnostics
A portable and low-cost diagnostic device has been developed at EPFL. This microfluidic tool, which has been tested with Ebola, requires no bulky equipment. It is thus ideally suited for use in remote regions.

Contact: francesco.piraino@epfl.ch
francesco.piraino@epfl.ch
41-767-851-370
Ecole Polytechnique Fédérale de Lausanne

Public Release: 19-Feb-2016
Seeking Zika: Where and when will Zika-carrying mosquitoes strike next?
Zika: the virus has emerged as a major public health threat that's rapidly spreading through South and Central America and the Caribbean.
National Science Foundation

Contact: Cheryl Dybas
cdybas@nsf.gov
703-292-7734
National Science Foundation

Public Release: 19-Feb-2016
Science
Researchers discover new Ebola-fighting antibodies in blood of outbreak survivor
A research team that included scientists from The Scripps Research Institute has identified a new group of powerful antibodies to fight Ebola virus. The antibodies, isolated from the blood of a survivor of the 2014 Ebola outbreak and the largest panel reported to date, could guide the development of a vaccine or therapeutic against Ebola.
National Institutes of Health, NIH/National Institute of Allergy and Infectious Diseases Center for Excellence in Translational Research, National Science Foundation fellowship, Defense Advanced Research Projects Agency

Contact: Madeline McCurry-Schmidt
madms@scripps.edu
858-784-9254
Scripps Research Institute

Public Release: 19-Feb-2016
Lancet Respiratory Medicine
Blood test could transform tuberculosis diagnosis, treatment in developing countries
A simple blood test that can accurately diagnose active tuberculosis could make it easier and cheaper to control a disease that kills 1.5 million people every year.

Contact: Jennie Dusheck
dusheck@stanford.edu
650-725-5376
Stanford University Medical Center

Public Release: 18-Feb-2016
Engineering to the rescue: Fighting kidney disease in rural Sri Lanka
Backed by a grant from the US Environmental Protection Agency (EPA), an interdisciplinary, student-led team from New Jersey Institute of Technology is building a low-cost water filter for villagers in the north central farming region of Sri Lanka who are suffering from high rates of chronic kidney disease.
US Environmental Protection Agency

Contact: Tanya Klein
klein@njit.edu
New Jersey Institute of Technology

Public Release: 18-Feb-2016
Proceedings of the National Academy of Sciences
Scientists discover way to potentially track and stop human and agricultural viruses
The discovery has broad ranging applications in stopping viral outbreaks such as hepatitis C in humans and a number of viruses in plants and animals because it applies to many viruses in the largest category of viral classes -- positive-strand RNA viruses.

Contact: Zeke Barlow
bzeke@vt.edu
540-231-5417
Virginia Tech

Public Release: 18-Feb-2016
PLOS Pathogens
Wolbachia parasite superinfection: A new tool to fight mosquito arbovirus transmission
Aedes aegypti mosquitoes transmit a number of pathogens, including the Dengue, Chikungunya, and Zika viruses. The Wolbachia bacterium can be introduced into the Aedes aegypti population and then block virus replication in the infected mosquito host. As with any antiviral strategy, the potential development of resistance by the virus is a concern. A study published on Feb. 18, 2016 in PLOS Pathogens reports on a strategy to make it harder for Dengue (and possibly other viruses) to develop Wolbachia resistance.

Contact: Cameron Simmons
csimmons@unimelb.edu.au
PLOS

Public Release: 17-Feb-2016
AIDS Research and Human Retroviruses
Progress toward an HIV cure highlighted in special issue of AIDS Research and Human Retroviruses
A cure for HIV/AIDS is the ultimate goal of rapidly advancing research involving diverse and innovative approaches. A comprehensive collection of articles describing the broad scope and current status of this global effort is published in a special issue of AIDS Research and Human Retroviruses.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 17-Feb-2016
Trends in Parasitology
Virginia Tech researchers suggest gene drive strategy to combat harmful virus spread
Researchers discuss how recent breakthroughs in CRISPR-Cas9 gene editing technology coupled with theirdiscovery last year of a male sex determining gene Nix could be a winning combination for tipping the male-female mosquito ratio in the wild.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Lindsay Key
ltkey@vt.edu
540-231-6594
Virginia Tech

Showing releases 126-150 out of 1221.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>